General
Preferred name
LEDIPASVIR
Synonyms
Ledipasvir (diacetone) ()
GS-5885 diacetone ()
GS-5885 acetone ()
Ledipasvir acetone ()
GS5885 ()
Ledipasvir (GS 5885) ()
GS-5885 ()
Ledipasvir (acetone) ()
Ledipasvir (D-tartrate) ()
GS-5885 D-tartrate ()
Ledipasvir diacetone ()
Ledipasvir acetonate ()
Ledipasvir-d6 ()
P&D ID
PD009401
CAS
1441674-54-9
1256388-51-8
1502654-87-6
1502655-48-2
2050041-12-6
Tags
available
drug
Approved by
EMA
FDA
First approval
2014
Drug Status
approved
Drug indication
Hepatitis C virus infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Ledipasvir acts against HCV and is categorized as a direct-acting antiviral agent (DAA).; ; At a dose of 120 mg twice daily (2.67 times the maximum recommended dosage), ledipasvir does not prolong QTc interval to any clinically relevant extent [FDA Label].
DESCRIPTION
Ledipasvir is an orally available, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex .
(GtoPdb)
DESCRIPTION
Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively).
GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing. (BOC Sciences Bioactive Compounds)
GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing. (BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
18
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
888.41
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
4
Rotatable Bonds
10
Ring Count
10
Aromatic Ring Count
5
cLogP
8.61
TPSA
174.64
Fraction CSP3
0.47
Chiral centers
6.0
Largest ring
6.0
QED
0.11
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HCV Protease
HCV
GT1a
GT1b
HCV NS5A protein inhibitor
SARS-CoV
Pathway
Metabolic Enzyme/Protease
Anti-infection
Microbiology&virology
Proteases/Proteasome
MOA
HCV Protease inhibitor
HCV inhibitor
Indication
hepatitis C
Solubility
Soluble in DMSO
Source data
